Bluebird Bio Inc (BLUE) 157.18 $BLUE The Zacks
Post# of 273333
Posted On: 07/29/2015 12:22:53 PM
Bluebird Bio Inc (BLUE) 157.18 $BLUE
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), LGND: 103.20 (-2.64), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), LGND: 103.20 (-2.64), AMGN: 171.86 (-0.88), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32), CELG: 133.93 (-1.49)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), NBIX: 50.03 (-1.89), ISIS: 53.13 (-1.27), SRPT: 31.80 (-0.23), RCPT: 227.79 (+0.63)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 157.18 (-3.14)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 157.18 (-3.14), CELG: 133.93 (-1.49)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 157.18 (-3.14)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 157.18 (-3.14), DRNA: 12.61 (-0.13), ALNY: 128.18 (-1.58), TKMR: 10.30 (+0.03), JUNO: 48.09 (-0.53), CELG: 133.93 (-1.49)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 157.18 (-3.14), HZNP: 36.90 (-1.42), AAL: 41.05 (-0.12), SDRL: 9.58 (+0.60), HNT: 66.16 (+0.12)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 17.96 (-0.22), BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), GILD: 116.83 (+3.76), AZN: 32.84 (+0.03), AMGN: 171.85 (-0.89), JUNO: 48.09 (-0.53), SRNE: 19.76 (-0.65), XLRN: 28.59 (-0.30), CELG: 133.93 (-1.49)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 157.18 (-3.14), KITE: 70.00 (-1.91), ADMS: 25.70 (-0.84), ACHN: 8.40 (-0.01)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 157.18 (-3.14), GILD: 116.83 (+3.76), MNKD: 4.46 (-0.36), PBYI: 83.66 (-3.56), KERX: 7.90 (-0.19), CELG: 133.93 (-1.49)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 157.18 (-3.14), KITE: 70.00 (-1.91), CLLS: 35.64 (-0.74), JUNO: 48.09 (-0.53), CYAD: 57.09 (+0.25), CELG: 133.93 (-1.49)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.24 (unch), NFLX: 107.31 (+0.41), BLUE: 157.18 (-3.14), AMZN: 527.32 (+1.29), TSLA: 266.61 (+1.79), KITE: 70.00 (-1.91), LBIO: 8.57 (-0.24), JUNO: 48.09 (-0.53), EGRX: 92.75 (-0.09)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.24 (unch), NFLX: 107.31 (+0.41), BLUE: 157.18 (-3.14), AMZN: 527.32 (+1.29), TSLA: 266.61 (+1.79), KITE: 70.00 (-1.91), LBIO: 8.57 (-0.24), JUNO: 48.09 (-0.53), EGRX: 92.75 (-0.09)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), LGND: 103.20 (-2.64), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), LGND: 103.20 (-2.64), AMGN: 171.86 (-0.88), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32), CELG: 133.93 (-1.49)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), NBIX: 50.03 (-1.89), ISIS: 53.13 (-1.27), SRPT: 31.80 (-0.23), RCPT: 227.79 (+0.63)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 157.18 (-3.14)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 157.18 (-3.14), CELG: 133.93 (-1.49)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 157.18 (-3.14)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 157.18 (-3.14), DRNA: 12.61 (-0.13), ALNY: 128.18 (-1.58), TKMR: 10.30 (+0.03), JUNO: 48.09 (-0.53), CELG: 133.93 (-1.49)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 157.18 (-3.14), HZNP: 36.90 (-1.42), AAL: 41.05 (-0.12), SDRL: 9.58 (+0.60), HNT: 66.16 (+0.12)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 17.96 (-0.22), BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), GILD: 116.83 (+3.76), AZN: 32.84 (+0.03), AMGN: 171.85 (-0.89), JUNO: 48.09 (-0.53), SRNE: 19.76 (-0.65), XLRN: 28.59 (-0.30), CELG: 133.93 (-1.49)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 157.18 (-3.14), KITE: 70.00 (-1.91), ADMS: 25.70 (-0.84), ACHN: 8.40 (-0.01)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 157.18 (-3.14), GILD: 116.83 (+3.76), MNKD: 4.46 (-0.36), PBYI: 83.66 (-3.56), KERX: 7.90 (-0.19), CELG: 133.93 (-1.49)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 157.18 (-3.14), KITE: 70.00 (-1.91), CLLS: 35.64 (-0.74), JUNO: 48.09 (-0.53), CYAD: 57.09 (+0.25), CELG: 133.93 (-1.49)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.24 (unch), NFLX: 107.31 (+0.41), BLUE: 157.18 (-3.14), AMZN: 527.32 (+1.29), TSLA: 266.61 (+1.79), KITE: 70.00 (-1.91), LBIO: 8.57 (-0.24), JUNO: 48.09 (-0.53), EGRX: 92.75 (-0.09)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.24 (unch), NFLX: 107.31 (+0.41), BLUE: 157.18 (-3.14), AMZN: 527.32 (+1.29), TSLA: 266.61 (+1.79), KITE: 70.00 (-1.91), LBIO: 8.57 (-0.24), JUNO: 48.09 (-0.53), EGRX: 92.75 (-0.09)
(0)
(0)